Clarinex D 24 Hour is owned by Merck Sharp Dohme.
Clarinex D 24 Hour contains Desloratadine; Pseudoephedrine Sulfate.
Clarinex D 24 Hour has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Clarinex D 24 Hour are:
Clarinex D 24 Hour was authorised for market use on 03 March, 2005.
Clarinex D 24 Hour is available in tablet, extended release;oral dosage forms.
The generics of Clarinex D 24 Hour are possible to be released after 28 September, 2022.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6979463 | MERCK SHARP DOHME | Stable extended release oral dosage composition |
Mar, 2022
(10 months ago) | |
US7820199 | MERCK SHARP DOHME | Stable extended release oral dosage composition |
Mar, 2022
(10 months ago) | |
US7820199
(Pediatric) | MERCK SHARP DOHME | Stable extended release oral dosage composition |
Sep, 2022
(4 months ago) |
Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient
Market Authorisation Date: 03 March, 2005
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic